BiondVax will Present Clinical Results and the Company's Strategy for Pandemic Preparedness Ahead of Flu Outbreak at the World Health Organization's Key Influenza Meeting

Nes Ziona, Israel – February 17, 2014 – BiondVax (TASE: BNDX), developer of a universal flu vaccine, announced today that it will present at the World Health Organization (WHO)'s invitation-only meeting for influenza vaccine experts, which will be held May 5-7, 2014 in Geneva, Switzerland. The conference is part of WHO's Initiative for Vaccine Research and will focus on flu vaccination developments, with the goal of promoting achievement of long term, efficient protection of the global population against a broad array of influenza strains. Dr. Tamar Ben-Yedidia, BiondVax’s Chief Scientist, will present the results of BiondVax's various studies and the Company's strategy for pandemic preparedness ahead of flu outbreak, as part of a session on new approaches for broadly protective flu vaccines. Key stakeholders in the global vaccination industry, as well as representatives from regulatory bodies, top tier academic research labs and opinion leaders will also attend the closed meeting."We are excited to participate in this important event, which provides the Company with a unique opportunity to present its achievements and pandemic preparedness plans in front of global decision and policy makers in the flu space. Governments and health organizations around the world look to the WHO for guidance about influenza policies and therefore it is critical for the Company’s success to be there", said Ron Babecoff, CEO of BiondVax.This WHO meeting is a closed-door event that is attended only by organizations and companies selectively invited to participate, with just a few participants given the opportunity to present. The topics presented at the conference go through a process of review and selection, and the meeting is reported in a peer-reviewed article. There will be representatives from foundations such as Bill and Melinda gates foundation and the major flu vaccine manufacturers, including Sanofi, GSK, Novartis, Baxter and bioCSL. The pivotal role of the WHO in the influenza arena is indicated by the wealth of programs currently run by this organization, including, Global Influenza Program (GIP), Global Action Plan for Influenza Vaccines (GAP), Strategic Advisory Group of Experts (SAGE) on Immunization Pandemic Influenza Preparedness (PIP) Framework and Global Influenza Surveillance and Response System (GISRS).